Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals

Ergomed Acquires ADAMAS Consulting Group

February 9, 2022

Healthcare Services

Ergomed plc has acquired ADAMAS Consulting Group Limited for a cash consideration of £25.6 million (enterprise value £24.2m), adding a specialist regulatory compliance and quality assurance capability to its pharmaceutical services offering. ADAMAS, which recorded £8.5m revenue and £1.8m adjusted EBITDA in 2021, will continue to operate independently with its senior management retained and is expected to be immediately accretive to Ergomed's earnings while expanding the Group's global reach.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Alexion Pharmaceuticals Acquires Portola Pharmaceuticals

May 5, 2020

Biotechnology

Alexion Pharmaceuticals agreed to acquire Portola Pharmaceuticals in a cash tender offer at $18.00 per share to add Portola’s Factor Xa inhibitor reversal agent Andexxa and diversify Alexion’s commercial portfolio beyond its complement franchise. The transaction, unanimously approved by both boards, was expected to close in the third quarter of 2020 and will be funded with Alexion’s cash on hand.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Bora Pharmaceuticals Acquires Upsher-Smith Laboratories

August 5, 2025

Pharmaceuticals

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.

ADAMA Ltd. Acquires AgriNova New Zealand Ltd. (Grochem)

December 6, 2022

Agriculture

ADAMA Ltd. has acquired AgriNova New Zealand Ltd., trading as Grochem, a Wellington-based developer and manufacturer of crop protection products, plant growth regulators and biosolutions. The deal strengthens ADAMA's presence in New Zealand and expands its product capability into biologicals, plant nutrition and PGRs.